Check Point Software Technologies fell nearly 9% on July 31 after its Q2 results disappointed, and the post-earnings analyst scramble has left the Street more divided than it was heading into the print.
The options market flagged the anxiety first. The put/call ratio jumped to 0.51 on July 31 — three standard deviations above its 20-day average of 0.42 — making it the most defensive reading in months outside of the June 30 spike. That is a sharp pivot from the relatively calm setup that preceded the report, when the ratio had been running in a tight band near 0.40 for most of July. Peers told a different story on the week: MANH surged 26% and CRWD added 4%, while CHKP gave back 2.6%. The divergence underlines how the earnings miss put CHKP firmly out of step with the broader cybersecurity complex.
Short interest, by contrast, is not the source of pressure here. Estimated shares short fell nearly 20% over the week to roughly 5.2 million, continuing the retreat from a mid-July peak near 6.5 million. Borrow availability has eased further to 874% — meaning lenders hold almost nine shares for every one currently borrowed — and cost to borrow runs at just 0.52%, barely above where it started the month. The lending market is telling a story of shorts leaving, not piling in, and there is no squeeze dynamic in play.
The analyst response to the print was fragmented in a way that captures the uncertainty around CHKP's transition. Several firms moved in conflicting directions on the same day. Wells Fargo cut its target to $130 from $140, while UBS nudged its target up to $135 from $130 — both keeping neutral-equivalent ratings. Stifel raised its target to $130 from $120, also staying on Hold. Susquehanna, a more constructive voice, lifted its target to $150. The mean consensus target now sits at $146, implying roughly 15% upside to the current $127 price, but that figure masks a wide spread of views. JP Morgan's downgrade last week to Neutral — from Overweight, at a $135 target — remains the most significant recent shift in conviction. The EV/EBITDA multiple compressed roughly a full turn over the past month, now running near 9.4x, reflecting the reset in expectations.
The bull-bear debate maps cleanly onto the go-to-market overhaul. Bulls point to Infinity platform adoption, emerging CTEM traction, and a subscription engine that continues to grow even as product revenue stumbles. Bears flag slowing forward EPS estimates — the 12-month forward EPS growth score ranks in the 14th percentile — and a reorganization that has now visibly disrupted two consecutive quarters. The ORTEX short score has drifted down to 45.7 from above 50 earlier in the month, reflecting the combination of falling short interest and loose borrow conditions; it no longer signals elevated short-side conviction.
Founder Gil Shwed holds 24.4% of shares. Recent insider activity has been modest sell-side: the Executive Chairman and a Director each sold 25,000 shares in June at prices between $122 and $140, before the latest leg lower. Those transactions reduce the insider bullish signal somewhat, though the quantum is small relative to Shwed's dominant stake.
The stock's next scheduled earnings event is not yet confirmed, which makes the near-term focus almost entirely about whether management commentary on the go-to-market transition — and any improvement in product revenue — begins to pull the fragmented analyst community back toward a consistent view.
See the live data behind this article on ORTEX.
Open CHKP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
